Overview
Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated With Bispecific Antibodies for R/R Multiple Myeloma
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
The expanding armamentarium of therapies for relapsed/refractory (R/R) multiple myeloma (MM) shifts the therapy selection process from a simple algorithmic approach to an individualized approach that requires consideration of the nature of relapse, previous therapies, treatment-related toxicities, as well as patient comorbidities and preferences. But many clinicians lack knowledge around the MOAs of novel therapies, including bispecific antibodies which have a unique set of toxicities. Ensuring optimal treatment outcomes for patients with R/R MM requires a well-coordinated multidisciplinary/multispecialty team to have a clear understanding of these adverse reactions and strategies to monitor and mitigate treatment-related adverse events associated with bispecific antibodies. This learning hub provides multidisciplinary clinicians with the education and resources needed to effectively translate the latest evidence into routine clinical practice.
This activity is intended for academic and community hematologists/oncologists, oncology nurses, oncology APPs, oncology pharmacists and other members of the multidisciplinary oncology team, primary care physicians, emergency department physicians and infectious disease specialists who help recognize and mitigate potential adverse events, as well as provide supportive care for patients with R/R MM.
Despite recent advances in treatment, MM is still considered an incurable malignancy; even with aggressive first-line therapy, most patients will relapse, and the 5-year overall survival is only 58%. The pursuit for tolerable and effective treatments in the R/R setting, especially for heavily treated patient populations, has resulted in novel therapies, including bispecific antibodies that target B-cell maturation antigen (BCMA) as well as a novel target in MM, G protein-coupled receptor, family C, group 5, member D (GPRC5D). These therapies are more accessible than CAR T-cell therapy. However, they have the potential for unique adverse events, some of which may be serious, such as cytokine release syndrome, neurotoxicity, and infections. As such, patients are typically hospitalized during step-up dosing to ensure proper pretreatment, monitoring, and supportive care. The approved GPRC5D/CD3 bispecific antibody talquetamab is also associated with a unique set of adverse events since GPRC5D is expressed by many tissues. The multidisciplinary team must have a clear understanding of these adverse reactions to monitor and manage them effectively when they occur.
Upon completion of this activity, learners will be able to:
- Outline potential toxicities and adverse events associated with bispecific antibodies used in the treatment of relapsed/refractory (R/R) multiple myeloma (MM)
- Discuss strategies to monitor and mitigate adverse events associated with bispecific antibodies for R/R MM
- Apply tactics to improve care coordination and patient communications around treatment-related adverse events in diverse patients with R/R MM
Content is displayed in these sections:
• Available Bispecific Antibodies for R/R MM
• Monitoring for Potential Toxicities and Adverse Effects
• Multidisciplinary Management of AEs
• Communication Between Patients and Their Clinical Team
• Care Coordination for Transitions to Outpatient Care
• Available Bispecific Antibodies for R/R MM
• Monitoring for Potential Toxicities and Adverse Effects
• Multidisciplinary Management of AEs
• Communication Between Patients and Their Clinical Team
• Care Coordination for Transitions to Outpatient Care
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland Clinic
Cleveland, OH
Rebecca LaRue, PharmD, BCOP
Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy
Team Lead Hematology/Oncology Pharmacy
Rush University Medical Center
Chicago, IL
Hans Lee, MD
Associate Professor
Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland Clinic
Cleveland, OH
Rebecca LaRue, PharmD, BCOP
Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy
Team Lead Hematology/Oncology Pharmacy
Rush University Medical Center
Chicago, IL
Hans Lee, MD
Associate Professor
Director, Multiple Myeloma Clinical Research
Department of Lymphoma/Myeloma
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Consultant: Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Pfizer, Sanofi
Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose
Hans Lee, MD
Consultant: AbbVie, Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini Silicon Biosystems, Pfizer, Regeneron, Takeda
Grants/Research Support: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Takeda
The following financial relationships have been provided:
Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Consultant: Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Pfizer, Sanofi
Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose
Hans Lee, MD
Consultant: AbbVie, Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini Silicon Biosystems, Pfizer, Regeneron, Takeda
Grants/Research Support: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Takeda
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: linvoseltamab, ententamig (ABBV-383), and HPN-217. These agents are not approved for the management of R/R MM as of 1/23/2025.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: linvoseltamab, ententamig (ABBV-383), and HPN-217. These agents are not approved for the management of R/R MM as of 1/23/2025.
This activity will take approximately 90 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.5 contact hours.
ACPE Universal Activity Number: 0396-0000-24-026-H01-P
Activity Type: Application
Release Date: 2/3/2025
Expiration Date: 2/3/2026
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
